Healthcare / BiotechnologyTaiwan
$21.00
-0.05 (-0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $43.1M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.3B
P/E
N/A
•EV/EBITDA
33.8x
↑ROE
-0.1%
↓Gross Margin
44.4%
↓Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.2%
FCF CAGR
—
FCF margin
-2.9%
FCF / Net income
8.79x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $351.3M · net income $-1.1M · FCF $-10.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $351.3M | $351.3M | $355.3M | $382.1M | $411.8M |
| Net Income | $-1.1M | $-1.1M | $61.6M | $43.7M | $74.8M |
| EBITDA | $27.0M | $27.0M | $103.3M | $81.0M | $129.6M |
| EPS | — | — | 1.02 | 0.72 | 1.23 |
| Gross Margin | 44.4% | 44.4% | 46.0% | 45.5% | 48.9% |
| Operating Margin | 5.0% | 5.0% | 9.5% | 11.6% | 15.8% |
| Net Margin | -0.3% | -0.3% | 17.3% | 11.4% | 18.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.01 | 0.01 |
| Current Ratio | 14.10 | 14.10 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-10.0M | $-10.0M | $43.1M | $47.3M | $126.0M |
| Returns | |||||
| ROE | -0.1% | -0.1% | 4.7% | 3.4% | 5.8% |
| Valuation | |||||
| P/E | — | — | 29.46 | 50.56 | 31.38 |
| EV/EBITDA | 33.78 | 33.78 | 13.54 | 22.12 | 15.32 |
| P/B | 1.01 | 1.01 | 1.39 | 1.72 | 1.81 |
| Growth & Yield | |||||
| Revenue Growth | -1.1% | -1.1% | -7.0% | -7.2% | — |
| EPS Growth | — | — | 41.7% | -41.5% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.6%
Start / end P/E
n/dx → n/dx
EPS bridge
1.02 → n/d
Residual
-30.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.